Exibindo 931 - 960 de 2728
In a pioneering initiative, the Foundation inaugurates this Monday (13/12), COVID-19 Biobank (BC19-Fiocruz). Located in Rio de Janeiro, at Expansão campus, BC19-Fiocruz will enable the design and conduct of research, technological development and clinical trials related to COVID-19, regardless of the geographic location of human biological material and viruses. With the capacity to store up to one and a half million samples of human and non-human biological materials, the Foundation's new unit will make a decisive contribution to Brazilian science.
Marcelo Queiroga, minister of Health, and…
Article
A research published today by The Lancet - one of the most prestigious scientific journals focused on the medical field in the world - brought together experts to explain how the economic downturn will affect for years and will be worse in developing countries. Without a consensus for preventive action, families and communities will be disproportionately affected. In the long run, inequalities in health, physical and socioeconomic well-being will widen worldwide. Fiocruz president, Nísia Trindade Lima, is one of the authors.
Image: Nailana Thiely/ Ascom Uepa
These…
Article
Designated by the United Nations, December 12th is celebrated every year as International Universal Health Coverage Day. The theme this year is Leave no one’s health behind: Invest in Health Systems for All - an issue that gained even more significance as the COVID-19 pandemic rolled on. This year’s campaign will feature a video showing people from all over the world who have shown leadership and vision in this matter, the so-called “Champions”. Among those invited to record a message is Fiocruz president, Nísia Trindade Lima, “for her personal leadership and for the work of the Foundation on…
Article
Fifteen years after visiting Fiocruz as a tourist, Pietro Lazzeri returned to the Foundation on Tuesday (12/07), this time as Switzerland ambassador. In office for six months, he met with Fiocruz members at the Fiocruz Global Health Center (CRIS/Fiocruz), where he proposed to expand technical and scientific cooperation. He also visited Bio-Manguinhos, where he found out that some of the machines used in the production of the COVID-19 vaccine came from his country.
Ambassador Pietro Lazzeri (at left) and Fiocruz met Fiocruz members at Fiocruz Golbal Health Center (Photo: Peter Ilicciev)…
Article
For one week Fiocruz will be at Expo Dubai. Starting on December 28th, visitors will be able to learn a little more about the Foundation's work and even take a virtual tour of Campus Manguinhos at the Brazil Pavilion. The World Expo takes place every five years and brings themes such as technology and sustainability. It began on October 1st, surrounded by care so that visitors can have interactive participation, but without crowds.
The Fiocruz exhibition project proposes to discuss health technology, access to health as a universal right, and health in the 2030 Agenda by approaching the…
Article
O Complexo Industrial de Biotecnologia em Saúde (Cibs) do Instituto de Tecnologia em Imunobiológicos (Bio-Manguinhos/Fiocruz) teve homologado (30/12) o vencedor da licitação para a sua construção, no campus de Santa Cruz, na Zona Oeste do Rio de Janeiro. O resultado foi publicado no Diário Oficial da União (DOU) e a empresa vencedora foi o Consórcio do Empreendimento NCPFI RJ. Com o processo concluído, o próximo passo será a assinatura do contrato para início das obras do futuro empreendimento, que será o maior centro de produção de produtos biológicos da América Latina e um dos…
Article
The Oswaldo Cruz Foundation, by means of the Fio-Schisto, the Translational Research Program in Schistosomiasis, informs that researcher Otávio Pieri, of the Oswaldo Cruz Institute (IOC), was invited to become part of the World Health Organization (WHO) group on schistosomiasis and helminth diseases transmitted through the soil (geo helminth diseases). Fio-Schisto is bound to the Vice-Presidency of Biological Research and Collections.
The invitation highlights that schistosomiasis and helminth diseases transmitted through the soil are a significant public health issue at a global level, which…
Article
The search for a coordinated solution to a common problem brought together representatives from Brazil, Argentina, Paraguay, Uruguay, and Bolivia this Tuesday (9/11) in the auditorium of the Immunobiological Technology Institute (Bio-Manguinhos). Organized by the Presidency Pro Tempore of Brazil in Mercosur, the Technical Seminar on Access to COVID-19 Vaccines: National Strategies and Possibilities of Expansion of the Regional Productive Capacity brought the sharing of experiences and challenges. The proposals that emerged in the debate - such as the suggestion of mapping the capacities and…
Article
Last Thursday (25 November) the Oswaldo Cruz Foundation, by means of its Immunobiological Technology Institute (Bio-Manguinhos/Fiocruz), submitted to the Brazilian Health Regulatory Agency (Anvisa) a request of post-registration alteration of its COVID-19 vaccine (recombinant), asking to include the Institute as the manufacturing unit of the Active Pharmaceutical Ingredient (API). Check out this 360º view of the production area for the Brazilian API for vaccines, at Fiocruz.
Five batches of Brazilian API have been produced, and four of them are currently going through analytical…
Article
In 2018, the king of the Yoruba people, Ooni of Ife, Oba Adeyeye Enitan Babatunde Ogunwus, visited Fiocruz and introduced the idea of a partnership in the field of traditional medicine and integrative health practices. Because of the COVID-19 pandemic, the conversation was stalled, but it was resumed this Wednesday (November 24th) with a visit of a delegation from the Palace of Ife to the Foundation.
(Photo: Pedro Paulo Gonçalves)
The delegation was led by the kings Ajero of Ijero (from the Ekiti state) and Apomu of Alapomu (from the Osun state), along with the Oduduwa Heritage…
Article
Severe cases of COVID-19 are related to the ageing of the immune system and to acute immunodeficiency. It is what the new study led by the Oswaldo Cruz Institute (IOC/Fiocruz) and by the Federal University of Rio de Janeiro (UFRJ) shows, published in the academic journal Journal of Infectious Diseases.
By analyzing blood samples of patients that have been hospitalized with the disease, the researchers detected signs of hyperactivity, exhaustion and ageing of the defense cells known as T helper cells. According to scientists, the data shows loss of responsiveness of these cells in severe COVID…
Article
“One mistake, one correction”: according to Carlos Morel, a researcher from the Brazilian state of Pernambuco, former Fiocruz president and current coordinator of the Center for Technological Development in Health (CDTS), this is how the world works. Last Tuesday (23 November), after attending the first meeting of the Scientific Advisory Group for the Origins of Novel Pathogens (SAGO), a group formed by the World Health Organization (WHO), Morel defended the mass sequencing of circulating virus, an idea he hopes to gain traction with the new group. “It is important to sequence what’s out…
Article
The first dose protects, but immunization requires a second dose and varies according to the age group and the time interval between doses. These are some conclusions of the pre-publication study that evaluated the effectiveness of the first dose of the AstraZeneca/Fiocruz vaccine against symptomatic cases of COVID-19 in the population of Complexo da Maré, in Rio de Janeiro (RJ). A 42.4% protection against symptomatic cases was estimated 21 days after the first dose of the vaccine. “It has a good result for containing symptomatic cases, but the second dose is essential to guarantee more…
Article
With two actions this week, Fiocruz became even more engaged in the fight against Hansen's, a neglected disease that had its situation aggravated during the COVID-19 pandemic. On Wednesday (11/17), the Foundation signed a Cooperation Agreement for joining the global campaign Don't Forget Hansen's Disease, with the state government and other partners, in addition to lighting the castle with purple at night as one of the actions to raise awareness. This Thursday (11/18), Fiocruz deepened the debate during the 1st Symposium on Neglected Diseases Fiocruz-Novartis: focus on Chagas and Hansen's…
Article
Sociologist and president of Fiocruz, Nísia Trindade Lima was appointed for The World Academy of Sciences for the advancement of science in developing countries (TWAS). The appointment was in the Academy’s General Meeting, on November 1st, as part of its 15th general conference.
Nísia is one of the 20 women who were appointed, in a total of 58 new members (Photo: Reproduction)
TWAS has the goal of bringing different scientific societies of developing countries closer, to promote its sustainable prosperity through science and technology, supporting researchers by granting scholarships and…
Article
There are a lot of statements, and a lot of commitments as well, but there is a lack of distinction of responsibilities and of the obligation in fulfilling the goals set, which hinders the operation of the G20. That is what the participants in the latest Advanced Seminar of the Fiocruz Global Health Center (CRIS/Fiocruz) point out. The G-20 Webinar: What we should expect from the richest people in the world in global and planetary health? analyzed the conclusions of the summit of the 19 countries that have the world’s main economies and the European Union.
For Paulo Esteves,…
Article
In another huge step to the internationalization of education, Fiocruz updated the ordinance that regulates the dual-degree stricto sensu graduation program regime with foreign higher education institutions regarded as of strategic relevance for the Foundation, no. 508, of 2021. The initiative allows students to get dual-degrees or titles in master's and doctorate's degrees. With this regime, when finishing the program, the student receives a diploma from a foreign institution that is part of the cooperation, along with a Fiocruz diploma.
The cooperation convention establishes the conditions…
Article
Last Thursday (28 October) Fiocruz signed, during a ceremony that took place at the headquarters of AstraZeneca, in Cambridge, United Kingdom, a joint declaration of commitment for the acquisition of Active Pharmaceutical Ingredient (API) with the goal of producing 60 million doses of the COVID-19 vaccine (recombinant) in order to make up the deliveries of the Foundation for 2022. The commitment signed by the institutions aims to guarantee wide availability of vaccine doses for the first semester. With the guarantee of the imported ingredient, Fiocruz will be able to deliver, through the…
Article
A new study published in Nature Communications last Thursday (28/11) shows that two doses of the AstraZeneca vaccine, produced in Brazil by Fiocruz, provide high protection against the Gamma variant in people above 60 years old. Based on São Paulo, the research shows that the second dose increases protection against death by about 30% when compared to the first dose, reaching an effectivity of 93.6%. Carried out by 20 researchers in Brazil, the United States and Spain, the study called Effectiveness of the ChAdOx1 vaccine in older adults during the circulation of the Gamma variant in São…
Article
Ten years after its signing, the Rio Political Declaration on Social Determinants of Health is more relevant than ever, as shown by the impacts of the COVID-19 pandemic in the world. To celebrate the document’s tenth anniversary and evaluate the approaches adopted since, two webinars held last Thursday (21 October) brought together many actors that were crucial for the negotiations that culminated in the declaration and for the quest for its implementation. While the World Health Organization (WHO) organized the seminar Actions on the Social Determinants of Health Equity, opened by the…
Article
The team of the Viral Vaccines Laboratory of the National Institute for Quality Control in Health (INCQS/Fiocruz), which works with immunobiological drugs against rabies (LVV-Raiva), is participating in the second phase of an international study to replace potency assays in anti-rabies vaccines, traditionally made using mice for over 50 years.
Under code BSP148 and funded by the European Directorate for the Quality of Medicines and Healthcare (EDQM), an institution of the Council of Europe in charge of the issuing of the European Pharmacopoeia, the research aims to validate the immuno-…
Article
Production of the Fiocruz Active Pharmaceutical Ingredient (API) for COVID-19 vaccines is ongoing and is now moving on to a new and important phase of the process. Two pre-validation batches of the product manufactured by Fiocruz have been approved in all in-house quality tests and are now on their way to an external quality control at USA laboratories. At these labs, the samples will go through a complex testing process that involves 14 tests in addition to those carried out in Brazil, the longest of which takes 56 days to complete. This set of tests compare Brazilian and foreign APIs,…
Article
When Fiocruz joined the small summit of guest countries of the Global Sustainable Technology and Innovation Community (G-STIC) in 2018, the world still did not know Sars-CoV-2. Now, while the world population takes the vaccine for COVID-19, the fifth edition of the annual conference (the fourth with the participation of the Foundation), bets on a hybrid participation model from October 24th to 26th. The agenda includes both virtual and on-site sessions looking for new technological solutions to serve the society that are environmentally friendly and aimed at 9 of the 17 Sustainable…
Article
Would it be possible to establish a new food model without the large producers' participation? Finding this answer is an ongoing global challenge and resounded in the seminar Food security, health and pandemics in United Nations events, organized by the Fiocruz Global Health Center (CRIS/Fiocruz). Divergent analyses and opinions revealed behind the scenes of international decisions on hunger programs and inspired empathy in provocative, necessary and urgent reflections.
"Is it possible to think of an alternative food system without the large corporations' participation? In Chile, even Coca-…
Article
A cooperation that dates back to the beginning of the last century and that has been renovated and expanded over the decades was celebrated last Thursday (October 14th), with the visit of Portugal’s assistant secretary of Health, António Lacerda Sales, to Fiocruz. Accompanied by the Secretary of State of the Portuguese Communities, Berta Nunes, and by ambassador Luís Faro Ramos, among other members of the delegation, Sales was received by president Nísia Trindade Lima at the International Auditorium of the Sergio Arouca National School of Public Health (ENSP/Fiocruz), where they emphasized…
Article
After a one-year break due to the restrictions caused by the COVID-19 pandemic, the Fiocruz in Antarctica (Fioantar) project resumed its scientific excursions into the continent with a new departure this Wednesday morning (10/13). After a week of quarantine with actions to fight COVID-19, including diagnostic tests before and during the period, the Ary Rongel oceanographic support ship set sail to the Comandante Ferraz Antarctic Station carrying researcher Lucas Moreira. In November, three other Fioantar researchers - Maria Ogrzewalska, Harrison Magdinier Gomes, and Maithê Magalhães - will be…
Article
A study led by the Center for the Integration of Data and Knowledge on Health (Cidacs/Fiocruz Bahia) suggests that C-sections may be associated with a higher risk of infant mortality, with the exception of cases in which a medical indication is clear on this procedure, which is popularly known as “cesarean” in Brazil.
Photo: Courtesy
Using data collected and provided by the Ministry of Health on more than 17 million births in Brazil between 2012 and 2018, researchers from Brazil and from the United Kingdom observed that in the group with a low indication of C-section, this procedure was…
Article
Sociologist and Fiocruz president, Nísia Trindade Lima, presented last Friday (October 8th) the conference Pandemic and Social Inequalities: Challenges for Global Health. The event was part of the Global Health Colloquium Series, a biannual series of lectures by Princeton University's Program in Global Health. Nísia thanked the university and Brazil Lab for the invitation, a hub that connects researchers and professors interested in public management in the country. The mediation was by Arbela Griner, postdoctoral fellow of the Program and event organizer.
Values, total social fact, and…
Article
Fiocruz will be part, starting next week, of a Phase 3 international multicenter study with the drug Molnupiravir, manufactured by the pharmaceutical company MSD. The goal is to verify its efficiency to prevent the COVID-19 spread and transmission among people exposed to the Sars-CoV-2 virus. The study will occur simultaneously in seven centers in Brazil, two of which are under the Fiocruz responsibility: Mato Grosso do Sul and Rio de Janeiro. The coordination is under the responsibility of researchers Julio Croda and Margareth Dalcolmo.
To evaluate the Molnupiravir use as post-exposure…
Article